公开(公告)号：EP2035582A2

公开(公告)日：2009-03-18

申请号：EP07798679.2

申请日：2007-06-18

申请人： NOVARTIS AG ,  NOVARTIS-PHARMA GMBH

发明人： HE, Yunsheng ,  GOMEZ-MANCILLA, Baltazar ,  MEYER, Joanne ,  ROVELLI, Giorgio ,  KUHN, Rainer R. ,  BILBE, Graeme

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

摘要： The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression.

公开(公告)号：EP1809285A1

公开(公告)日：2007-07-25

申请号：EP05799805.6

申请日：2005-11-03

申请人： Novartis AG ,  NOVARTIS-PHARMA GMBH

发明人： KALKMAN, Hans, O. ,  NOZULAK, Joachim ,  VASSOUT, Annick ,  HURTH, Konstanze ,  FEUERBACH, Dominik ,  GENTSCH, Conrad ,  BILBE, Graeme

IPC分类号： A61K31/46 ,  A61K45/06

CPC分类号： A61K31/46 ,  A61K45/06 ,  A61K2300/00

摘要： Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.

公开(公告)号：EP1682103A1

公开(公告)日：2006-07-26

申请号：EP04790865.2

申请日：2004-10-26

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： AUBERSON, Yves ,  BILBE, Graeme ,  KUHN, Rainer, R. ,  VON MATT, Peter ,  RUEEGER, Heinrich ,  STAUFENBIEL, Matthias ,  WAGNER, Jürgen ,  ZIMMERMANN, Kaspar

IPC分类号： A61K31/00 ,  A61K31/496 ,  A61K31/517 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K31/00 ,  A61K31/496 ,  A61K31/517

摘要： The invention relates to the use of an inhibitor of formula (I), or a pharmaceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta, PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.

公开(公告)号：EP1596866A2

公开(公告)日：2005-11-23

申请号：EP04711352.7

申请日：2004-02-16

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： BILBE, Graeme ,  CRYAN, John, F. ,  GENTSCH, Conrad ,  MCALLISTER, Kevin, Hall ,  SCHMUTZ, Markus ,  VASSOUT, Annick

IPC分类号： A61K31/55

CPC分类号： A61K31/55

摘要： The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85 % S-enantiomer and not more than 15 % R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.

公开(公告)号：EP2142184A1

公开(公告)日：2010-01-13

申请号：EP08749978.6

申请日：2008-05-01

申请人： Novartis AG

发明人： BARDE, Yves-Alain ,  BILBE, Graeme ,  DEOGRACIAS, Ruben ,  KUHN, Rainer, R. ,  MATSUMOTO, Tomoya ,  MIR, Anis, Khusro ,  SCHUBART, Anna, Svenja

IPC分类号： A61K31/137 ,  A61P3/10 ,  A61P3/04 ,  A61P25/28 ,  A61P25/24 ,  A61P43/00

CPC分类号： A61K31/397 ,  A61K31/137 ,  A61K31/138 ,  A61K31/145 ,  A61K45/06

摘要： Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

公开(公告)号：EP2142184B1

公开(公告)日：2018-10-24

申请号：EP08749978.6

申请日：2008-05-01

申请人： Novartis AG

发明人： BARDE, Yves-Alain ,  BILBE, Graeme ,  DEOGRACIAS, Ruben ,  KUHN, Rainer, R. ,  MATSUMOTO, Tomoya ,  MIR, Anis, Khusro ,  SCHUBART, Anna, Svenja

IPC分类号： A61K31/397 ,  A61K31/137 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61P25/28 ,  A61P25/24 ,  A61P43/00

CPC分类号： A61K31/397 ,  A61K31/137 ,  A61K31/138 ,  A61K31/145 ,  A61K45/06

摘要： Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

公开(公告)号：EP2337566A1

公开(公告)日：2011-06-29

申请号：EP09736991.2

申请日：2009-10-21

申请人： Novartis AG

发明人： BILBE, Graeme ,  GOMEZ-MANCILLA, Baltazar ,  HOYER, Daniel ,  JOHNS, Donald ,  KALKMAN, Hans O. ,  MCALLISTER, Kevin Hall

IPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4439 ,  A61P25/06

CPC分类号： A61K31/4045 ,  A61K31/404 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/517 ,  A61K2300/00

摘要： The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT
1 B/1 D receptor agonist and at least one selective, competitive AMPA receptor antagonist being a 1 H-quinazoline-2,4-dione of formula (I) as defined in the claims; to their preparation; to their use as medicaments and to medicaments comprising them.